Generic cyclosporine formulations: More open questions than answers

Research output: Contribution to journalArticle

Abstract

The introduction of cyclosporine (CsA) in clinical practice has significantly improved patient and allograft survival after organ transplantation. The new microemulsion CsA formulation, Neoral, has been associated with a more reproducible absorption and a better patient outcome as compared to the old formulation Sandimmune. Recently, several generic CsA formulations have been tested as bioequivalent to Neoral. Bioequivalence tests have been performed in selected groups of young, healthy male volunteers usually in single-dose studies, and then extended to completely different population, such as transplant recipients. However, growing body of evidence shows that CsA pharmacokinetics in healthy subjects is different from that of transplant patients, treated chronically with CsA. Therefore, converting patients from Neoral to the new generic formulations could be detrimental, exposing patients to increased risk of graft function deterioration and graft loss. Thus, more research and more accurate bioequivalence tests are required to address the unanswered problems dealing with the generic CsA formulations.

Original languageEnglish
Pages (from-to)371-378
Number of pages8
JournalTransplant International
Volume18
Issue number4
DOIs
Publication statusPublished - Apr 2005

Fingerprint

Cyclosporine
Therapeutic Equivalency
Transplants
Healthy Volunteers
Organ Transplantation
Allografts
Pharmacokinetics
Research
Population

Keywords

  • Bioequivalence
  • Cyclosporine
  • Generic formulation
  • Organ transplantation

ASJC Scopus subject areas

  • Transplantation

Cite this

Generic cyclosporine formulations : More open questions than answers. / Cattaneo, Dario; Perico, Norberto; Remuzzi, Giuseppe.

In: Transplant International, Vol. 18, No. 4, 04.2005, p. 371-378.

Research output: Contribution to journalArticle

@article{20f31f95df94431ba7d41fcef0b58026,
title = "Generic cyclosporine formulations: More open questions than answers",
abstract = "The introduction of cyclosporine (CsA) in clinical practice has significantly improved patient and allograft survival after organ transplantation. The new microemulsion CsA formulation, Neoral, has been associated with a more reproducible absorption and a better patient outcome as compared to the old formulation Sandimmune. Recently, several generic CsA formulations have been tested as bioequivalent to Neoral. Bioequivalence tests have been performed in selected groups of young, healthy male volunteers usually in single-dose studies, and then extended to completely different population, such as transplant recipients. However, growing body of evidence shows that CsA pharmacokinetics in healthy subjects is different from that of transplant patients, treated chronically with CsA. Therefore, converting patients from Neoral to the new generic formulations could be detrimental, exposing patients to increased risk of graft function deterioration and graft loss. Thus, more research and more accurate bioequivalence tests are required to address the unanswered problems dealing with the generic CsA formulations.",
keywords = "Bioequivalence, Cyclosporine, Generic formulation, Organ transplantation",
author = "Dario Cattaneo and Norberto Perico and Giuseppe Remuzzi",
year = "2005",
month = "4",
doi = "10.1111/j.1432-2277.2005.00078.x",
language = "English",
volume = "18",
pages = "371--378",
journal = "Transplant International",
issn = "0934-0874",
publisher = "Blackwell Publishing Ltd",
number = "4",

}

TY - JOUR

T1 - Generic cyclosporine formulations

T2 - More open questions than answers

AU - Cattaneo, Dario

AU - Perico, Norberto

AU - Remuzzi, Giuseppe

PY - 2005/4

Y1 - 2005/4

N2 - The introduction of cyclosporine (CsA) in clinical practice has significantly improved patient and allograft survival after organ transplantation. The new microemulsion CsA formulation, Neoral, has been associated with a more reproducible absorption and a better patient outcome as compared to the old formulation Sandimmune. Recently, several generic CsA formulations have been tested as bioequivalent to Neoral. Bioequivalence tests have been performed in selected groups of young, healthy male volunteers usually in single-dose studies, and then extended to completely different population, such as transplant recipients. However, growing body of evidence shows that CsA pharmacokinetics in healthy subjects is different from that of transplant patients, treated chronically with CsA. Therefore, converting patients from Neoral to the new generic formulations could be detrimental, exposing patients to increased risk of graft function deterioration and graft loss. Thus, more research and more accurate bioequivalence tests are required to address the unanswered problems dealing with the generic CsA formulations.

AB - The introduction of cyclosporine (CsA) in clinical practice has significantly improved patient and allograft survival after organ transplantation. The new microemulsion CsA formulation, Neoral, has been associated with a more reproducible absorption and a better patient outcome as compared to the old formulation Sandimmune. Recently, several generic CsA formulations have been tested as bioequivalent to Neoral. Bioequivalence tests have been performed in selected groups of young, healthy male volunteers usually in single-dose studies, and then extended to completely different population, such as transplant recipients. However, growing body of evidence shows that CsA pharmacokinetics in healthy subjects is different from that of transplant patients, treated chronically with CsA. Therefore, converting patients from Neoral to the new generic formulations could be detrimental, exposing patients to increased risk of graft function deterioration and graft loss. Thus, more research and more accurate bioequivalence tests are required to address the unanswered problems dealing with the generic CsA formulations.

KW - Bioequivalence

KW - Cyclosporine

KW - Generic formulation

KW - Organ transplantation

UR - http://www.scopus.com/inward/record.url?scp=20444475424&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20444475424&partnerID=8YFLogxK

U2 - 10.1111/j.1432-2277.2005.00078.x

DO - 10.1111/j.1432-2277.2005.00078.x

M3 - Article

C2 - 15773953

AN - SCOPUS:20444475424

VL - 18

SP - 371

EP - 378

JO - Transplant International

JF - Transplant International

SN - 0934-0874

IS - 4

ER -